
USD $204.75
Lentris, containing the active ingredient Lenvatinib, is a targeted therapy used primarily for the treatment of certain types of cancer, including differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma. This medication works by inhibiting specific proteins that promote cancer cell growth and division.
Lentris is indicated for patients with:
Lenvatinib functions as a tyrosine kinase inhibitor, targeting receptors involved in tumor growth and angiogenesis. By blocking these pathways, Lentris helps to slow down or stop the progression of cancer.
The dosage of Lentris may vary based on the type of cancer being treated and the patient's overall health. It is typically taken orally, with or without food, at the same time each day. It is essential to follow the healthcare provider's instructions regarding dosage and duration of treatment.
Common side effects of Lentris may include:
Patients should report any severe or persistent side effects to their healthcare provider.
Before starting Lentris, patients should inform their healthcare provider of any pre-existing conditions, particularly heart problems, liver disease, or high blood pressure. Regular monitoring of blood pressure and liver function tests may be required during treatment.
Lentris may interact with other medications. Patients should provide their healthcare provider with a complete list of medications, including over-the-counter drugs and supplements, to avoid potential interactions.
Lentris (Lenvatinib) is a powerful treatment option for specific cancers, offering a targeted approach to therapy. Patients should work closely with their healthcare team to ensure the best outcomes while managing any side effects or concerns during treatment.